CorMedix Inc

CorMedix’s 2026 proxy: board re‑election, executive pay vote, auditor approval, governance tweaks, and shareholder‑friendly changes—key for investors.

CorMedix, a Nasdaq‑listed biopharma, showcases its cutting‑edge anti‑infective pipeline—DefenCath®, REZZAYO®—and strategic Melinta acquisition at the 2026 Needham Virtual Healthcare Conference, spotlighting growth in infectious & inflammatory therap…

CorMedix, a Nasdaq‑listed biopharma firm, is redefining infectious & inflammatory disease treatment with a robust pipeline and global expansion, offering investors a low‑P/E, growth‑oriented opportunity.

CorMedix Inc. has made a strategic acquisition of Melinta Therapeutics, valued at $300 million, to create a diversified specialty company with a strong presence in acute care settings.